LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...
Zacks Investment Research on MSN7d
Mirum's Heavy Dependence on Livmarli for Revenues Remains a WoeMirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...
The impressive growth of cholestatic pruritus market from $19.20 billion in 2024 to an estimated $20.28 billion in 2025. This rapid growth is fuelled by augmenting prevalence of skin disorders ...
Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...
It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.
Livmarli is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic ...
LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions expected to complete enrollment in 2026. Expect to initiate Phase 2 study for MRM-3379 in Fragile X Syndrome (FXS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback